EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/45615b363cefc5d589bec1d471e49176.pdf

Abstract Title

First Name *

Jonathan

Last Name *

Barratt

Co-author 1

Miguel Ángel Pérez Valdivia miguelangelperezvaldivia@gmail.com Hospital Virgen del Rocío Servicio de Nefrología, UGC Urología-Nefrología Seville

Co-author 2

Dario Roccatello dario.roccatello@unito.it San Giovanni Bosco Hub Hospital University Centre of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net) with Nephrology and Dialysis Unit and Centre of Immuno-Rheumatology and Rare Diseases (CMID), ASL Città di Torino and Department of Clinical and Biological Sciences of the University of Turin Turin

Co-author 3

Katherine Garlo katherine.garlo@alexion.com Alexion, AstraZeneca Rare Disease Global Medical Sciences Boston

Co-author 4

Kara Rice kara.rice@alexion.com Alexion, AstraZeneca Rare Disease Biostatistics Boston

Co-author 5

Richard Lafayette czar@stanford.edu Stanford University Medical Center Stanford Glomerular Disease Center Stanford

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15